Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial
Tetsuro Yoshida, Akihiro Nakamura, Junichi Funada, Mari Amino, Wataru Shimizu, Masayuki Fukuzawa, Saori Watanabe, Takuya Hayashi, Takeshi Yamashita, Ken Okumura, Masaharu Akao, Tetsuro Yoshida, Akihiro Nakamura, Junichi Funada, Mari Amino, Wataru Shimizu, Masayuki Fukuzawa, Saori Watanabe, Takuya Hayashi, Takeshi Yamashita, Ken Okumura, Masaharu Akao
No abstract availableKeywords: aged; anticoagulants; atrial fibrillation; edoxaban; hemorrhage; kidney; thromboembolism.
Figures
Relationship between stroke/systemic embolism or major bleeding and renal function in patients with nonvalvular atrial fibrillation. Kaplan-Meier curves and forest plots for stroke/systemic embolism and major bleeding in the edoxaban and placebo groups according to baseline creatinine clearance. CI indicates confidence interval; CrCl, creatinine clearance; and HR, hazard ratio.
References
- Okumura K, Akao M, Yoshida T, Kawata M, Okazaki O, Akashi S, Eshima K, Tanizawa K, Fukuzawa M, Hayashi T, et al. ; ELDERCARE-AF Committees and Investigators Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med. 2020; 383:1735–1745. doi: 10.1056/NEJMoa2012883
- Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016; 134:24–36. doi: 10.1161/CIRCULATIONAHA.116.022361
- Koretsune Y, Yamashita T, Kimura T, Fukuzawa M, Abe K, Yasaka M. Short-term safety and plasma concentrations of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal impairment. Circ J. 2015; 79:1486–1495. doi: 10.1253/circj.CJ-14-0942
Source: PubMed